COVID-19

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

01/19/2021

Excerpt from the Press Release: LEXINGTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 hours of testing positive for COVID-19 to…

Read More

Chest Imaging Shows Little Long-Term Lung Scarring from COVID-19

01/18/2021

Excerpt from the Article: How well a patient’s lungs recover post-COVID-19 infection is not necessarily linked with the severity of his or her disease course, but imaging shows that most patients do not experience long-term fibrosis. To date, little research has focused on lung health post-recovery, and not much is known about whether the lingering…

Read More

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

01/18/2021

Excerpt from the Press Release: Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Email Print Friendly ShareJanuary 14, 2021 07:30 ET | Source: Innovation Pharmaceuticals Inc. WAKEFIELD, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the…

Read More

COVID-19 Lung Involvement Captured on CT Can Help Predict Mortality Risk

01/16/2021

Excerpt from the Article: Chest CT scans can provide a volumetric analysis of lung consolidation in COVID-19-positive patients, helping providers with care management and better enabling them to pinpoint which patients could die in the hospital from the virus. In a study published Jan. 6 in the European Journal of Radiology Open, investigators from Michigan…

Read More

Mayo validates COVID-19 plasma treatment as public seeks vaccine

01/15/2021

Excerpt from the Article: Donor plasma from patients who have recovered from COVID-19 can reduce deaths in others if given early and at high enough doses, Mayo Clinic researchers found. The discovery validates one of COVID-19’s only known treatments, which will be relied on until an increase in vaccinations snuffs out the global pandemic, said…

Read More

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

01/15/2021

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing…

Read More

Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

01/14/2021

WARRINGTON, Pa., Jan. 6, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first patient in its Phase 2 clinical trial studying lucinactant in acute lung injury in adults with COVID-19 associated…

Read More

Study Finds Commonly Used Blood Pressure Medications Safe for COVID-19 Patients

01/14/2021

Excerpt from the Press Release: PHILADELPHIA—Medications to treat high blood pressure did not affect outcomes among patients hospitalized with COVID-19, found an international team led by researchers in the Perelman School of Medicine at the University of Pennsylvania. The study, published today in The Lancet Respiratory Medicine, is the first randomized controlled trial to show…

Read More

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

01/13/2021

Excerpt from the Press Release: Burlingame, CA, and Chicago, IL – January 10, 2021 – Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced…

Read More

AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies

01/12/2021

Excerpt from the Press Release: SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its manuscript describing the development of ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively…

Read More